Dexcom announced on Tuesday a man-made intelligence feature for its Stelo continuous glucose monitor that provides users personalized insight into the impact of meals, sleep and activity on their glucose levels. It's the primary iteration of a brand new generative AI platform the corporate has been constructing Google Cloud.

Stelo is an over-the-counter CGM that pierces the skin to measure blood sugar levels in real time. The sensor was launched in August and might be utilized by any adult who doesn’t take insulin.

The report reflects Dexcom's efforts to make Stelo more personalized and interesting for consumers as the corporate works to enter a brand new market.

“The main feedback we're getting is that users want to see more,” said Jake Leach, chief operating officer at Dexcom, in an interview with CNBC. “They are making an investment and carrying the product, and they want to be able to get the most value out of all the data they generate.”

Dexcom uses Google's Gemini models and its Vertex AI platform as the muse for its latest AI offering. Vertex AI allows developers to construct applications that synthesize several types of data, which might be notoriously difficult in healthcare.

Leach said Dexcom can be exploring how its generative AI platform may very well be utilized in its other CGM products, but the corporate is taking a very cautious approach due to patients' reliance on it to forestall medical emergencies.

“I really felt like Stelo was the right place for it for the first time,” he said.

An existing Insights report was already available to users within the Stelo app, nevertheless it followed a more standard template format each week. Dexcom expects the AI-generated report might be more priceless to users since it is personalized, Leach said.

If there may be per week wherein a user doesn’t exercise enough, for instance after eating, the report includes relevant suggestions and academic materials to assist.

Stelo's AI reports don’t provide users with medical advice, although Dexcom used a U.S. Food and Drug Administration AI framework to guide development of the feature, Leach said. The FDA approved Stelo in March.

Ultimately, Dexcom wants to make use of its generative AI platform to offer users with real-time feedback somewhat than simply weekly reports. The company can be exploring how the technology could function a predictive indicator of potential problems, just like the check engine light on a automotive.

“It gives you a sense of what might be going on and gives you recommendations on where you should go for further advice,” said Chris Sakalosky, vice chairman of strategic industries at Google Cloud, in an interview with CNBC.

Dexcom's updated weekly report was rolled out to Stelo users this week.

Abbott Laboratories announced Thursday that its over-the-counter Lingo continuous glucose monitor is out there within the U.S. starting at $49.

Lingo is a component of a brand new class of consumer-friendly biosensors that may help people learn the way their bodies reply to food, exercise, sleep and stress. These devices, called continuous glucose monitors, are small sensors which can be poked through the skin to measure glucose levels in real time. Glucose is a sugar molecule that comes from food and is the body's predominant source of energy.

Continuous glucose monitors have served as a tool for patients with diabetes, but Lingo will not be intended for diabetes management. Instead, it’s designed for adults who don’t take insulin and need to “improve their overall health and well-being,” in response to a press release.

Everyone's glucose levels fluctuate, but persistently high levels may cause more serious health problems equivalent to metabolic disease, insulin resistance and heart disease, Abbott said. The company argues Lingo can educate users about existing habits and help them manage their glucose levels in a healthier way.

“That's really the goal, not only to see and understand what's going on in your body, but to be able to improve that, to build those healthy habits that drive those changes,” said Ben Fohner, the top of Abbott's Lingo app, in an interview with CNBC.

Abbott already offers continuous glucose monitors for diabetes patients within the US and needs to overcome a very recent market with Lingo. About one in three Americans, for instance, suffers from prediabetes, but these patients are generally not eligible for prescriptions or insurance coverage for the monitors.

Now they will pay for the sensors out of pocket, with no prescription. Users should purchase one sensor online for $49, two sensors for $89 or six sensors for $249, Abbott said. Each sensor is worn on the upper arm for as much as 14 days.

Olivier Ropars, Abbott's divisional vice chairman for Lingo, said the corporate decided to supply three different pricing options so curious consumers aren't delay by a long-term commitment. A customer can decide to buy only one sensor and check out it out for a number of weeks.

“We want to make it as accessible and affordable as possible,” Ropars said in an interview with CNBC.

Abbott's competitor Dexcom can also be eyeing the prediabetes market. In late August, the corporate launched its over-the-counter continuous glucose monitor tailored to that focus on group. Dexcom's device is known as Stelo and is out there within the U.S. for $89 a month. Patients with type 2 diabetes who don’t take insulin may also use it, the corporate said.

The U.S. Food and Drug Administration approved Dexcom's Stelo in March and cleared two over-the-counter continuous glucose monitoring systems from Abbott in June. One of Abbott's systems was Lingo, and the second system, called Libre Rio, is meant for patients with type 2 diabetes who don’t take insulin.

Although type 2 patients who don't take insulin could technically use Lingo, Ropars said Abbott primarily recommends Libre Rio since it was designed specifically for them. The company declined to say when Libre Rio can be available.

The Lingo app

Like many continuous glucose monitors, Lingo transmits data wirelessly to an app. When users open it, they see a real-time display of their glucose data, updated every minute.

These glucose levels are plotted on a graph that features a shaded area to point a “healthy range.” Fohner said Abbott's clinical team defines this range as 140 milligrams per deciliter to 70 milligrams per deciliter.

One of Abbott's predominant goals is to assist Lingo users learn more about glucose spikes, which occur when the quantity of sugar within the bloodstream rises quickly after which falls again. Glucose spikes often occur after eating.

Spikes can push a user's glucose above the healthy range, but they may also occur inside the healthy range. Limiting spikes and overall improving glucose management may help users improve their sleep and mood, manage their weight and proactively work on their future health, Abbott said.

To help users higher visualize the impact of their spikes, Abbott has developed a metric called the Lingo Count, an algorithm that assigns a numerical value to every glucose spike to represent how big the impact is. Each day, users have a goal Lingo Count that they wish to stay below.

Users can see this data in a second, more interactive glucose graph after they scroll down on Lingo's homepage. In the shaded area below a spike, a number is displayed that represents the Lingo counter for that spike.

“This is unique to Lingo, but actually the number is an indicator and a function of what your peak was, how long it lasted and what effect that peak had on your body,” Fohner said.

Users can analyze Lingo Count data and see the way it evolves over time and what time of day the strongest spikes occur. They may also enter competitions and access educational resources to learn reduce these spikes.

Ropars said metabolism doesn't change overnight and everybody's body works otherwise. He said Lingo can function a window to see how and why a user's glucose levels fluctuate. But the true value of Lingo lies within the support it might probably offer users as they fight to ascertain healthy habits, Ropars said.

“Many of our products today are geared towards helping people who have a chronic illness and are trying to get back on their feet,” he said. “This is the first time we've developed a product to help people, improve their daily lives and give them control of their health before they get sick.”

Dexcom on Monday announced its recent over-the-counter continuous glucose monitor Stelo is officially available within the US

Glucose is a form of sugar that humans get from food and is the body's major source of energy. Continuous glucose monitors (CGMs) are small sensors which might be inserted through the skin to measure glucose levels in real time. They are frequently prescribed to patients with diabetes because they can assist alert the patient, their family members, and their doctor to emergencies.

Stelo is primarily intended for patients with prediabetes or type 2 diabetes who don’t use insulin, although it’s also available for people without those conditions. Users should purchase a month's supply online for $99 or subscribe for $89 per thirty days.

Dexcom said in a press release that patients even have the choice to make use of their flexible spending accounts and health savings accounts to pay for Stelo.

The company already offers continuous glucose monitors for patients with Type 1 and Type 2 diabetes, but Stelo is Dexcom's first product that doesn't require a prescription. While most Type 1 patients can already get the sensors covered by insurance, Stelo is now accessible to thousands and thousands of Type 2 patients who previously couldn't get a prescription or coverage. It's also the corporate's official foray right into a recent and potentially lucrative prediabetes market.

Dexcom said in a press release that there are greater than 125 million Americans with prediabetes or type 2 diabetes who don’t use insulin. The company developed Stelo to show this group of patients how one can keep their glucose levels in a healthy range.

“The idea is to help people learn more about dietary habits and preferences over time and how those affect blood sugar,” said Jake Leach, chief operating officer at Dexcom, in an interview with CNBC. “It's about uncovering things you've never seen before and then using those to develop healthier habits.”

How it really works

The US Food and Drug Administration (FDA) approved Stelo in March. It was the primary over-the-counter continuous glucose monitor to be approved to be used, although Dexcom’s competitor, Abbottreceived approval for 2 similar devices in June.

Leach said Dexcom is working with Amazon to make Stelo deliveries. Users with a subscription can skip or adjust their delivery date, but it is going to typically be scheduled at 30-day intervals from their first login.

Stelo is worn on the upper arm and lasts 15 days before needing to get replaced. It is gray, concerning the size of 1 / 4 and about half an inch thick.

The sensor transmits data wirelessly to a smartphone app. During setup, users indicate whether or not they have type 2 diabetes, prediabetes, or not one of the above. This helps establish their “target range,” which is where Dexcom wants users to try to keep up their glucose levels. The goal range relies on established medical standards and is between 70 and 180 milligrams per deciliter for most individuals, in response to the American Diabetes Association.

When they open the Stelo homepage, they'll see their most up-to-date reading, which is updated every quarter-hour. They'll also see a graph of their every day readings, which incorporates a green shaded area indicating the goal range. If they scroll down, they'll see a summary of the time they've spent within the goal range over time.

Everyone's glucose levels are different, but Stelo sends users an alert when a major spike occurs. Glucose spikes occur when the quantity of sugar within the bloodstream rises quickly after which falls again. This often happens after eating.

In the short term, peaks could cause fatigue, but over time, high glucose levels can even result in more serious health problems comparable to diabetes, heart and kidney disease, in response to the Centers for Disease Control and PreventionFor this reason, Dexcom wants users to try to maintain their values ​​inside Stelo's goal range.

The tab next to the house page is the Events page, where Stelo users can log meals, activities, finger pricks or other notes. Leach said it's most vital for users to log an entry once they experience an enormous spike in order that they can reflect on what is likely to be causing it.

Stelo notifies users of notable spikes, in order that they won't necessarily be notified each time their levels go up. Leach says it is a conscious design decision meant to attract attention to the larger fluctuations patients experience.

“Even for someone whose blood sugar is normal and who has occasional spikes, the system looks for the biggest spikes and then tries to reach out to the user and say, 'OK, what happened there?'” he said.

And for users who wish to delve deeper into their blood sugar and understand the causes of blood sugar spikes, there may be a wealth of educational materials available within the app's Learn tab. The articles are short, sometimes just a couple of sentences long, and so they're divided into categories like “Stelo Basics,” “Glucose in Depth,” “Diet,” “Exercise,” “Sleep,” and “Stress.”

CNBC tests Stelo

I've been testing Stelo because the starting of August. Overall, I find it easy to make use of and helpful.

When my monitors arrived within the mail, my first task was to connect the sensor to my arm and pair it with the Stelo app. This process was very straightforward for me – the app guided me through each step with clear step-by-step instructions.

I cleaned the back of my right arm, placed the Dexcom applicator there, pressed the button, and the CGM turned on immediately. It's quick and doesn't hurt in any respect.

The monitor connects to the Stelo app via Bluetooth after which takes about half an hour to warm up.

This is where I initially encountered some issues. After my device warmed up, I received an error message saying “Temporary sensor issue”. The message told me to not remove the CGM and that the difficulty was only temporary. I left it on all day, but by the evening I noticed a slight bleeding. I made a decision to remove the sensor.

I attached one other CGM to my other arm, which warmed up and worked tremendous. I've been wearing it ever since and haven't had any issues with bleeding. Leach said if users have any issues with the product, they’ll send a message to the chat interface on Stelo's website to get a alternative device or have their questions answered there.

After I got my second sensor arrange and running, every thing went easily.

I discovered the Stelo app easy and straightforward to make use of. I never felt like I used to be overloaded with an excessive amount of data or too many notifications, and logging meals and exercise may be very straightforward. Users can even import their sleep and activity data from the Apple Health app or Android's Health Connect app, which I believe is a pleasant touch.

If that is your first time using a CGM, I definitely recommend reading through the articles on the Learn tab. I believe Dexcom does an incredible job of explaining in easy language what glucose is, what it affects, and why it's essential.

The longer I wear the sensor, the more I can tell that the algorithm is adapting to me and my habits. I don't get notified each time my blood sugar level rises, but I get alerted when there may be a very sharp rise. The app can be starting to acknowledge my patterns. For example, it recently told me that my blood sugar level rises between 5 and seven p.m., which is across the time I eat dinner.

Most of the time I even forget that I'm wearing a sensor. It's waterproof, so I didn't should worry about it once I was showering. And I didn't notice it once I was sleeping. I’d advise slightly caution when putting on long-sleeved clothes, because the sensor can get caught slightly, but you possibly can wear all types of garments and jackets over it with none problem.

In the short time I've been using Stelo, I've learned so much about how my body reacts to certain foods. Even small adjustments (eating carbs last, for instance) have helped me reduce spikes. It's easy to see how CGMs can function a beneficial window into the body. If you're on the lookout for a straightforward, accessible method to start understanding your glucose data, I believe Stelo is a solid option.